Introduction
3D strain analysis
Characteristics of 2D and 3D strain
Validation of 3D strain
Experimental studies | ||||||||||
Author Year (Ref.#) | Vendor | Materials | Reference | 3D regional LS | 3D regional CS | 3D regional RS | 3D regional AS | |||
Seo 2009 [14] | Toshiba | Sheep | Sonomicrometry | r = 0.89 p < 0.001 | r = 0.90 p < 0.001 | r = 0.84 p < 0.001 | NA | |||
Seo 2011 [15] | Toshiba | Sheep | Sonomicrometry | NA | NA | NA | r = 0.87 p < 0.001 | |||
Human studies | ||||||||||
Author Year (Ref.#) | Vendor | Subjects | Reference | 3D GLS | 3D GCS | 3D GRS | 3D GAS | 2D GLS | 2D GCS | 2D GRS |
Kleijn 2012 [16] | Toshiba | Volunteer | CMR tagging | NA | r = 0.80 p: NA | NA | NA | NA | NA | NA |
Luis 2014 [17] | GE | Patient | 2D LVEF | r = 0.74 p < 0.001 | r = 0.89 p < 0.001 | r = 0.86 p < 0.001 | r = 0.87 p < 0.001 | r = 0.86 p < 0.001 | r = 0.82 p < 0.001 | r = 0.67 p < 0.001 |
Luis 2014 [17] | GE | Patient | 3D LVEF | r = 0.75 p < 0.001 | r = 0.89 p < 0.001 | r = 0.87 p < 0.001 | r = 0.88 p < 0.001 | r = 0.86 p < 0.001 | r = 0.84 p < 0.001 | r = 0.64 p < 0.001 |
Obokata 2016 [18] | TomTec | Patient | CMR feature tracking | r = 0.87 p < 0.001 | r = 0.88 p < 0.001 | r = 0.82 p < 0.001 | NA | r = 0.83 p < 0.001 | r = 0.90 p < 0.001 | r = 0.69 p < 0.001 |
Feasibility of 3D strain
Direct comparisons of 2D and 3D strain values
Reference values for 3D GLS
Author year (Ref.#) | n | Race | Vendor | Tracking | Mean ± SD | LLN (Overall) (mean-1.96SD) | Mean ± SD male | Mean ± SD female | P (male vs. female) | LLN (Male) (mean-1.96SD) | LLN (Female) (mean-1.96SD) |
---|---|---|---|---|---|---|---|---|---|---|---|
Kaku 2014 [59] | 241 | Japanese/American | TomTec | Subendocardial | 19.6 ± 3.1% | 13.5% | 18.7 ± 2.8% | 20.6 ± 3.1% | < 0.001 | 13.2% | 14.5% |
Xia 2014 [60] | 153 | Chinese | Toshiba | Full myocardial | 15.2 ± 0.8% | 13.6% | NA | NA | NA | NA | NA |
Muraru 2014 [58] | 265 | European | GE | Full myocardial | 18.7 ± 2.6% | 13.5% | 17.8 ± 2.4% | 19.4 ± 2.6% | < 0.001 | 13.0% | 14.2% |
Muraru 2014 [58] | 265 | European | TomTec | Subendocardial | 20.4 ± 3.8% | 12.8% | 19.5 ± 3.8% | 21.1 ± 3.6% | < 0.001 | 11.9% | 13.9% |
Kleijn 2015 [61] | 303 | European/American | Toshiba | Full myocardial | 15.9 ± 2.4% | 11.2% | 15.5 ± 2.4% | 16.3 ± 2.3% | 0.003 | 10.8% | 11.8% |
Bernard 2017 [62] | 440 | European | TomTec | Subendocardial | 21.0 ± 2.6% | 15.9% | 20.4 ± 2.7% | 21.4 ± 2.4% | < 0.001 | 15.1% | 16.7% |
Kovacs 2019 [63] | 178 | European | Toshiba | Full myocardial | 16.1 ± 2.5% | 11.1% | NA | NA | NA | NA | NA |
Clinical applications of 3D strain
Ischemic heart disease
Author Year (Ref.#) | n | Patients | Vendor | Feasibility | Remarks | |||||
LV remodeling | ||||||||||
Abate 2012 [64] | 153 | Acute STEMI | GE | 96% (patients) | 1) Regional 3D LS of 11.1% had a > 90% sensitivity and specificity for predicting improvement of LV regional function. 2) 3D GLS had an incremental value over clinical and standard echocardiography parameters for predicting improvement of LVEF (> 5%). | |||||
Li 2012 [65] | 61 | Recent NSTEMI | Toshiba | 80% (patients) | 1) Regional AS > 23% at baseline had a 75% sensitivity and a 76% specificity for predicting improvement of LV regional function. 2) 3D GAS ≤32% after PCI predicted LV adverse remodeling with 86% sensitivity and 68% specificity. | |||||
Sugano 2017 [49] | 71 | Acute STEMI | Toshiba | 96% (patients) | 1) 3D GCS < 23% had an 84% sensitivity and a 74% specificity for predicting LV adverse remodeling. 2) 3D GAS < 31% had an 84% sensitivity and a 58% specificity for predicting LV adverse remodeling. | |||||
Xu 2017 [27] | 110 | Acute STEMI | GE | 91% (patients) | 1) 2D GLS, 3D GLS, 3D GAS, and 3D GRS were independent predictors of LV adverse remodeling. 2) 3D GLS < 12.6% had a 92% sensitivity and a 60% specificity for predicting LV adverse remodeling. 3) 3D GAS < 24.2% had a 92% sensitivity and a 46% specificity for predicting LV adverse remodeling. 4) AUC of 3D GLS (0.82) was significantly higher than that of 2D GLS (0.72), 3D GAS (0.68) and 3D GRS (0.68) for predicting LV adverse remodeling. | |||||
Transmurality of MI | ||||||||||
Hayat 2012 [30] | 25 | OMI | Toshiba | 76% (patients) 96% (segments) | 1) 2D LS and CS and all 3D regional strains were significantly different among segments derived from control subjects, those with non-transmural MI, and those with transmural MI. | |||||
Thorstensen 2013 [33] | 58 | RMI | GE | 62% (patients) 71% (segments) | 1) All 3D regional strains were significantly different among segments with no MI, those with non-transmural MI, and those with transmural MI. 2) All 3D regional strains predicted transmural MI (AUC: 0.73–0.87). 3) 2D GLS had a higher AUC (0.88) for the prediction of transmural MI than 3DGLS (0.73, p < 0.05). | |||||
Zhu 2014 [66] | 26 | AMI | Toshiba | Not described | 1. Regional 3D LS and 3D CS discriminated among segments with no MI, those with non-transmural MI, and those with transmural MI. | |||||
Aly 2016 [67] | 82 | LV dysfunction | Toshiba | 88% (segments) | 1. Regional 3D CS and 3D AS discriminated among segments with no MI, those with non-transmural MI, and those with transmural MI. 2. Regional 3D LS discriminated between segments with non-transmural MI and those with transmural MI. 3. Included 11 patients with non-ischemic LV dysfunction. | |||||
Sugano 2017 [49] | 71 | Acute STEMI | Toshiba | 95% (segments) | 1. Regional 2D CS, 3D CS, and 3D AS discriminated among segments with no MI, those with non-transmural MI, and those with transmural MI. 2. Regional 2D LS failed to differentiate between non-transmural MI and transmural MI. 3D LS failed to differentiate between no MI and non-transmural MI. | |||||
Infarct size | ||||||||||
Author Year (Ref.#) | n | Patients | Vendor | Correlation of infarction size | remarks | |||||
2D GLS | 3D GLS | 3D GCS | 3D GRS | 3DS | 3D AS | |||||
Hayat 2012 [30] | 25 | OMI | Toshiba | NA | r = 0.45 | r = 0.47 | r = 0.07 | r = 0.10 | r = 0.49 | |
Thorstensen 2013 [33] | 58 | RMI | GE | r = 0.67 | r = 0.42 | r = 0.47 | r = 0.48 | r = 0.52 | r = 0.50 | 2DGLS was more closely correlated with infarct size than 3DGLS. |
Zhu 2014 [66] | 26 | AMI | Toshiba | NA | r = 0.86 | r = 0.81 | r = 0.71 | NA | NA | |
Aly 2016 [67] | 71 | ICM | Toshiba | NA | r = 0.29 | r = 0.32 | r = 0.08 | r = 0.29 | r = 0.39 |
Cardio-oncology
Author Year (Ref.#) | Type of cancer | n | Treatment | Echo timing | Feasibility | CTRCD (%) | Pre-echo | Post-echo | Remarks |
---|---|---|---|---|---|---|---|---|---|
Mornos 2014 [71] | various | 79 | Anthracycline (100%) | Before and at 12 and 36 weeks | 3D STE: 75% | 14% | 3D GLS: 19.4 ± 2.3% 3D GCS: 21.4 ± 1.7% 3D GRS: 42.4 ± 5.3% | 17.5 ± 2.4%* 20.9 ± 1.7% 37.6 ± 5.4%* | Δ3D GLS was an independent predictor for future CTRCD. Δ3D GLS of 13.7% had an 88% sensitivity and a 71% specificity for CTRCD. |
Tarr 2015 [39] | various | 25 | Anthracycline (28%) | Before and 3 months | 2D STE: 100% 3D STE: 100% | NA | 2D GLS: 15.0 ± 4.2% 2D GRS: 28.0 ± 10.6% 3D GLS: 13.0 ± 2.6% 3D GCS: 21.0 ± 4.5% 3D GRS: 28.0 ± 12.8% | 14.0 ± 4.6%* 21.0 ± 11.5%* 12.0 ± 2.2% 22.0 ± 4.7% 26.0 ± 14.5% | 3D global strains did not show a significant decrease after therapy. |
Santoro 2017 [26] | breast | 100 | Anthracycline (100%) | Before and at 4 months | 2D STE: 91% /90% 3D vol.: 88% /67% 3D STE: 84% /60% | NA | 2D GLS: 22.2 ± 2.3% 3D LVEF: 62 ± 7% 3D GLS: 17.6 ± 3.2% 3D GCS: 16.8 ± 2.8% 3D GAS: 30.2 ± 4.5% 3D GRS: 47.4 ± 9.2% | 20.1 ± 6.6%* 60 ± 7%* 16.2 ± 3.5%* 15.2 ± 2.9%* 27.5 ± 5.4%* 43.1 ± 10.7% | % reduction of 2D GLS > 15% was observed in 17 patients (17%). 3D-derived LVEF decreased < 50% in 4 out of 67 patients (6%). |
Song 2017 [72] | lymphoma | 89 | Anthracycline (100%) | Before, at 3 weeks, and at the end of Tx. | 2D STE: 93% /93%/93% 3D STE: 93% /93%/93% | NA | 2D LVEF: 70 ± 3% 2D GLS: 21.5 ± 2.5% 3D GLS: 21.8 ± 2.9% 3D GCS: 29.9 ± 4.4% | 69 ± 3% 20.7 ± 2.1% 27.5 ± 4.5%* 27.3 ± 5.0%* | 2D GLS and LVEF did not change, but 3D GLS and 3D GCS were significantly reduced 3 weeks after therapy. |
Zhang 2018 [73] | breast | 142 | Anthracycline (100%) Trastuzumab (9%) | Before and annually | 3D STE: 94% | NA | 3D LVEF: 56.8% 3D GLS:16.8% 3D GCS: 27.3% 3D principal strain: 29.9% | 51.5%* 15.3%* 24.2%* 26.0%* | 3D LVEF, 3D GLS, 3D GCS, and 3D principal strain were associated with concurrent and subsequent changes in systolic function. |
Chen 2019 [74] | breast | 83 | Anthracycline (100%) | Before, during, and after Tx. | 3D STE:100% | NA | 3D GLS 18.1 ± 2.2% 3D GCS 18.7 ± 2.6% 3D GAS 34.1 ± 2.8% 3D GRS 44.9 ± 5.2% | 14.9 ± 2.5%* 15.7 ± 0.3%* 23.9 ± 2.6%* 43.3 ± 4.9% | There was a significant correlation between 3D GAS and the culminating dose of anthracycline (r = 0.77). |
Cruz 2019 [53] | breast | 105 | Anthracycline (100%) Trastuzumab (52%) | Before and during Tx. | 2D STE: 100% (patients)/ 96% (segments) 3D STE: 100% (patients)/ 94% (segments) | 23% | 2D LVEF: 66 ± 8% 2D GLS: 21.1 ± 3.0% 3D LVEF: 62 ± 6% 3D GLS: 15.6 ± 3.4% 3D GCS: 14.0 ± 4.0% 3D GAS: 27.0 ± 8.5% 3D GRS: 42.0 ± 17.0% | 58 ± 11%* 18.8 ± 3.1%* 54 ± 9%* 10.9 ± 4.1%* 11.0 ± 5.0%* 20.0 ± 9.0%* 28.5 ± 17.5%* | Percent reduction of 3D GCS (cut-off value of 34.2%) and that of 3D GRS (34.5%) predicted CTRCT with 70% diagnostic accuracy. |
Subclinical LV dysfunction
Left ventricular hypertrophy
Author Year (Ref #) | Type of disease (number) | Purpose | Remarks |
---|---|---|---|
Baccouche 2012 [77] | CA (n = 12) / HCM (n = 12) | To differentiate two pathologies. | 1) Basal LS, CS and RS were significantly reduced in patients with CA compared with HCM. 2) Regional strain values were irreversibly correlated with LGE, and the best correlation was observed between RS and LGE (r = −0.82) |
Aly 2014 [78] | HCM mutation carriers (n = 23) / HCM (n = 28) / control (n = 29) | To detect early changes in myocardial mechanics in HCM mutations. | 1) There were no significant differences in 3D global/regional strains between HCM mutations and control subjects. 2) 3D global/regional LS and AS were significantly impaired in HCM compared with HCM mutations. 3) 3D GCS and 3DGRS were not different between HCM and HCM mutations. |
Tadic 2015 [38] | HT with normal LV geometry (n = 85) / concentric LV remodeling (n = 28) / eccentric nondilated LVH (42) / concentric LVH (n = 30) / dilated and concentric-dilated LVH (n = 12) | To investigate LV mechanics in HT with different geometric patterns | 1) 2D and 3D global strains decreased normal geometry, followed by concentric remodeling, eccentric nondilated LVH, concentric LVH, dilated LVH and concentric dilated LVH. 2) Reduced 2D and 3D strains were associated with concentric and dilated LVH patterns independent of demographic and clinical parameters. |
Urbano-Moral 2015 [79] | AL amyloidosis (n = 40) | To detect cardiac involvement. | 1) 3D GLS and GCS were significantly lower in patients with cardiac involvement than those without. 2) Prominent reduction of LS/CS was observed in the basal myocardium. |
Voilliot 2015 [80] | HCM (n = 40) / control (n = 53) | To assess impact of hypertrophy on strains. | Compared to control subjects, 1) 3D GLS, GAS, and GRS were significantly lower in HCM patients. 2) No significant differences in 3D GCS were noted. 3) 3D regional LS/AS was significantly depressed irrespective to the degree of hypertrophy. 4) 3D regional CS was higher in no or mildly hypertrophied segments. |
Ternacle 2017 [52] | Athlete with moderate LVH (n = 25) / Athlete without LVH (n = 25) / HCM (n = 25) / control (n = 25) | To differentiate patients with HCM from athletes with moderate LVH. | 1) 2D GLS and 3D GLS were significantly lower in HCM than athletes with moderate LVH. 2) 2D LV dyssynchrony index (SD of time to peak LS in 16 segment model) had a highest AUC for identifying HCM in the presence of moderate LVH. 3) 3D GCS was not different between the two groups. |
Cho 2017 [46] | Severe AS with normal LVEF (≥ 55%, n = 45) / control (n = 18) | To evaluate early myocardial dysfunction | 1) 2D GLS and 3D GLS were significantly impaired in severe AS patients with increased LV wall thickness compared with normal LV wall thickness. 2) 3D GCS, GAS, and GRS did not show any differences between the two groups. |
Pradel 2019 [81] | AL amyloidosis (n = 58) / control (n = 21) | To detect LV dysfunction. | 1) There were no significant differences in 3D LVEF and 3D global strains between Mayo Clinic Stage I AL amyloidosis and control subjects. 2) 3D LVEF and 3D global strains decreased according to the advanced Mayo Clinic stage. |
Valvular heart disease
Cardiac resynchronization therapy
Prognostic value
Author Year (Ref. #) | n | Etiology | 2DSTE | 3DSTE | Events | Remarks |
---|---|---|---|---|---|---|
Chang 2014 [23] | 200 | Diverse | Not described | Toshiba | HF hospitalization or CD (n = 32) | 1) All 3D global strains were associated with outcomes. 2) 3D GLS and 3D GRS had an incremental value over 3D LVEF. |
Nagata 2015 [25] | 104 | Asymptomatic severe AS with preserved LVEF (> 50%) | TomTec | TomTec | MACE or AVR (n = 33) | 1) 2D GLS, 3D GLS, and 3D GRS were associated with outcomes. 2) AUC of 3D GLS was significantly larger than that of 2D GLS and 3D GRS. 3) 3D GLS was an only significant predictor after adjusting LV mass index and mean PG. |
Sun 2016 [96] | 66 | Hemodialysis | Not performed | TomTec | MACE (n = 23) | 3D GLS and 3D GRS were associated with MACE. |
Casaa-Rojo 2016 [84] | 45 | Asymptomatic severe MR with Preserved LVEF (> 60%) | Not performed | Toshiba | MACE, LVEF< 60% or MV surgery (n = 15) | 3D GLS, GAS, and GCS were associated with outcomes. |
Shin 2016 [95] | 96 | Acute MI | Toshiba | Toshiba | MACE (n = 12) | 3D GAS was associated with outcomes. |
Howard-Quijano 2017 [47] | 163 | Cardiac surgery | GE | GE | MACE (n = 34) | All 3D global strains were associated with MACE. |
Medvedofsky 2018 [97] | 416 | Diverse | Philips | TomTec | CV death (n = 114) | 1) 2D/3D LVEF, 2D/3D GLS were significantly associated with outcomes. 2) 3D GLS was the strongest predictor for CV mortality. |
Medvedofsky 2019 [98] | 104 | 30–50% of 2D LVEF | Philips | TomTec | CV death (n = 32) | 1) Not 2D LVEF/2D GLS and 3DLVEF but 3D GLS was associated with outcomes. |